NEUROTRANSMITTER PATTERN CORRELATES OF PAIN

这项拟议工作的长期目标是开发一种基于 关于神经递质(单胺类、多肽/前体、 代谢物和结合物)，可用于指导和开发治疗 并预测三叉神经痛(TGM)和其他疾病患者的预后 面部疼痛的各种形式。 最多32个多电极传感器与液体接口的新技术 层析(n-ELC)提高了分辨率和灵敏度 传统的LC技术大约提高了20倍，允许 直接进样中100~200种化合物的同时拆分 脑脊液(CSF)0.5-1pg水平，同时 单胺类和多肽的大部分成分测定 在有限数量的分析条件下涉及痛苦的系统。 第一阶段提案的目标是改进同步的方法 测定单胺类化合物和多肽；提供一种 关于脑脊液中单胺和多肽水平的最初数据主体来自 三叉神经池和TGM后窝及其他面部疼痛 受试者，并比较两个不同受试者的数据 样本类型和不同诊断面部疼痛的受试者之间 有显著的变化。

A long range aim of this proposed work is to develop a clinical test based on patterns of neurotransmitters (monoamines, peptides/precursors, metabolites and conjugates) which can be used to guide and develop therapy and predict outcome in patients with trigeminal neuralgia (TGM) and other forms of facial pain. New technology interfacing up to 32 multiple electrode sensors with liquid chromatography (n-ELC) has improved the resolution and sensitivity of conventional LC techniques by approximately a factor of twenty, allowing simultaneous resolution of 100-200 compounds in directly injected cerebrospinal fluid (CSF) at the 0.5-1 pg level and simultaneous determination of most of the components of monoaminergic and peptide systems implicated in pain with a limited number of analytical conditions. The aims of the Phase I proposal are to refine methods for simultaneous determination of monoaminergic compounds and peptides; to provide an initial body of data on levels of monoamines and peptides in CSF from the trigeminal cisterns and posteria fossa of TGM and other facial pain subjects, and to compare the data within subjects for the two different sample types and among subjects for different diagnoses of facial pain for significant variations.